Healthy Clinical Trial
Official title:
The Physiological Chronobiome Modified by Age, Sex and Under Evoked Conditions
Verified date | January 2024 |
Source | University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators piloted the characterization of the human chronobiome. Now, this line of research is extended to explore physiological chronobiome modulated by sex, age and under evoked conditions.
Status | Active, not recruiting |
Enrollment | 48 |
Est. completion date | June 4, 2027 |
Est. primary completion date | January 4, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Young: 18-30 years of age, Old: 55-75 years of age 2. Apparent healthy 3. BMI (body mass index) up to 27.4 4. Upper arm with intact skin, i.e. without areas of breached or injured skin visible, for ambulatory blood pressure (ABP) measurements, 5. Own and use a smartphone. Exclusion Criteria: 1. History of severe psychiatric illness or cognitive conditions, for example (mania, schizophrenia, or mental retardation; 2. Shift work, defined as recurring work between 22:00-05:00; 3. A diagnosis of clinically significant obstructive sleep apnea; 4. Serum creatinine > 1.5 mg/dl in men or >1.3 mg/del in women; 5. Significant liver disease (>3x upper limit of normal); 6. Diabetes mellitus; 7. Past diagnosis of gastroesophageal reflux disease, 8. Transmeridian travel across =3 time zones in the two weeks before the 48hr deep phenotype sessions; 9. Use of oral or intravenous antibiotics in the 6 months prior to enrollment; 10. Subjects, who have received an experimental drug, used an experimental medical device within 30 days prior to screening, or who gave a blood donation of = one pint within 8 weeks prior to screening; 11. > 2 drinks of alcohol per day; 12. Use of drugs assessed in the urinary drug test; 13. Nursing or pregnant (pregnancy will be repeatedly assessed at the beginning of each of the four inpatient visits, i.e. prior to the start of blood draws); 14. Use of pacemaker or implantable Cardioverter Defibrillator (ICD); 15. Bilateral mastectomy; 16. History of Raynaud's phenomenon; 17. Known allergy against natural latex rubber (contained in ABP bladder and tubing); 18. Subjects taking medication with alpha-blockers. |
Country | Name | City | State |
---|---|---|---|
United States | Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania |
United States,
Skarke C, Lahens NF, Rhoades SD, Campbell A, Bittinger K, Bailey A, Hoffmann C, Olson RS, Chen L, Yang G, Price TS, Moore JH, Bushman FD, Greene CS, Grant GR, Weljie AM, FitzGerald GA. A Pilot Characterization of the Human Chronobiome. Sci Rep. 2017 Dec 7;7(1):17141. doi: 10.1038/s41598-017-17362-6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent difference in the number of proteins with post-translational modifications found in blood samples from young versus old participants | High-throughput proteomics analysis determines the number of proteins with and without post-translational modifications. This will explore what effect age has on the number of proteins with post-translational modifications. | 48 hours | |
Secondary | Percent difference in the number of proteins with post-translational modifications found in blood samples from female versus male participants | High-throughput proteomics analysis determines the number of proteins with and without post-translational modifications. This will explore what effect sex has on the number of proteins with post-translational modifications. | 48 hours | |
Secondary | Percent difference in the number of proteins with post-translational modifications found in blood samples from female versus male participants and by age | High-throughput proteomics analysis determines the number of proteins with and without post-translational modifications. This will explore whether an interaction between age and sex has an effect on the number of proteins with post-translational modifications. | 48 hours | |
Secondary | Percent difference in environmental light exposure between young versus old participants | Wrist actigraphy collects personal light exposure | 48 hours | |
Secondary | Percent difference in environmental light exposure between young versus old participants and by sex | Wrist actigraphy collects personal light exposure | 48 hours | |
Secondary | Percent difference in physical activity between young versus old participants | Wrist actigraphy records accelerometer data to calculate physical activity | 48 hours | |
Secondary | Percent difference in physical activity between young versus old participants and by sex | Wrist actigraphy records accelerometer data to calculate physical activity | 48 hours | |
Secondary | Percent difference in systolic blood pressure readings between young versus old participants | Ambulatory blood pressure measurements (ABPM) collect blood pressure readings | 48 hours | |
Secondary | Percent difference in systolic blood pressure readings between young versus old participants and by sex | Ambulatory blood pressure measurements (ABPM) collect blood pressure readings | 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |